Dicerna Pharma: Two Targets in Lilly Collaboration Meet Proof of Principle
November 12 2021 - 8:54AM
Dow Jones News
By Chris Wack
Dicerna Pharmaceuticals Inc. said that Eli Lilly and Co. has
declared proof of principle for the first two targets in the
companies' exclusive relationship in neurodegeneration and pain
therapies, under the companies' global research and licensing
collaboration.
This milestone triggers two single-digit multimillion-dollar
milestone payments to Dicerna, which the company expects to receive
in the fourth quarter.
"We are very pleased to announce Lilly's selection of two
extrahepatic targets for advancement to preclinical development and
initiation of associated IND-enabling studies under our discovery,
development and licensing agreement," said Bob D. Brown, chief
scientific officer at Dicerna. "These molecules represent the first
targets under our collaboration with Lilly to address tissues
outside the liver, highlighting the further expansion of our
growing pipeline of RNAi therapeutics that address multiple tissues
and cell types."
Dicerna and Lilly entered into a global licensing and research
collaboration in 2018 focused on the discovery, development and
commercialization of potential new therapies for cardiometabolic
disease, neurodegenerative diseases and pain. Including the two
targets highlighted on Friday, there are seven candidates in
preclinical or clinical development.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
November 12, 2021 08:39 ET (13:39 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Dicerna Pharmaceuticals (NASDAQ:DRNA)
Historical Stock Chart
From Oct 2024 to Nov 2024
Dicerna Pharmaceuticals (NASDAQ:DRNA)
Historical Stock Chart
From Nov 2023 to Nov 2024
